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A B S T R A C TBackground: Statins are lipid-lowering drugs that reduce the risk of
cardiovascular events in patients with diabetes. Objectives: The
objective of this study was to determine whether statin treatment
for primary prevention in newly diagnosed type 2 diabetes is cost-
effective, taking nonadherence, baseline risk, and age into account.
Methods: A cost-effectiveness analysis was performed by using a
Markov model with a time horizon of 10 years. The baseline 10-year
cardiovascular risk was estimated in a Dutch population of primary
prevention patients with newly diagnosed diabetes from the Gronin-
gen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) data-
base, using the United Kingdom Prospective Diabetes Study risk
engine. Statin adherence was measured as pill days covered in the
IADB.nl pharmacy research database. Cost-effectiveness was meas-
ured in costs per quality-adjusted life-year (QALY) from the health
care payers’ perspective. Results: For an average patient aged 60 years,
the base case, statin treatment was highly cost-effective at €2245 persee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.12.010
ries@rug.nl.
ndence to: Folgerdiena M. de Vries, Department of
Groningen,A. Deusinglaan 1, 9713 AV Groningen,QALY. Favorable cost-effectiveness was robust in sensitivity analysis.
Differences in age and 10-year cardiovascular risk showed large differ-
ences in cost-effectiveness from almost €100,000 per QALY to almost
being cost saving. Treating all patients younger than 45 years at diabetes
diagnosis was not cost-effective (weighted cost-effectiveness of almost
€60,000 per QALY). Conclusions: Despite the nonadherence levels
observed in actual practice, statin treatment is cost-effective for primary
prevention in patients newly diagnosed with type 2 diabetes. Because of
large differences in cost-effectiveness according to different risk and age
groups, the efﬁciency of the treatment could be increased by targeting
patients with relatively higher cardiovascular risk and higher ages.
Keywords: cardiovascular risk management, cost-effectiveness,
statins, type 2 diabetes.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The prevalence of diabetes is growing in The Netherlands, as in
many countries worldwide, because of aging of the population
and the occurrence of diabetes at younger ages [1]. Patients with
type 2 diabetes have an increased risk of cardiovascular compli-
cations [2]. These complications reﬂect a high burden for health
and cause substantial costs related to diabetes [3–5]. Statins are
lipid-lowering drugs that have been shown to reduce the risk of
cardiovascular and cerebrovascular events in patients with dia-
betes [6–8]. After 2006, the Dutch guidelines for diabetes and
cardiovascular risk management changed and recommended
statin treatment for the prevention of cardiovascular events for
practically all patients with type 2 diabetes, unless they have a
low cardiovascular risk [9,10]. Although risk tables changed in
recent guidelines, it was found using different risk calculation
methods that few patients with type 2 diabetes are at such low
risk [11]. Also, in other countries, statin treatment is recom-
mended for a large proportion of the diabetes population [12,13].
Previous pharmacoeconomic analyses on the primary pre-
vention of cardiovascular and cerebrovascular events estimatedthat statin treatment is likely to be cost-effective in patients
with type 2 diabetes [14–16]. These pharmacoeconomic results,
however, are limited because they made use of data from the
same clinical trial, which included a restricted patient popula-
tion with high adherence levels. Adherence to statins is a well-
known problem in clinical practice [17,18], and therefore impor-
tant to take into account when assessing cost-effectiveness.
Furthermore, attention should be paid to the risk level where
treatment becomes cost-effective. Greving et al. [19] recently
demonstrated for a hypothetical primary prevention population
that statins were not cost-effective in persons at low risk in The
Netherlands. Whether this may also be true for patients with
type 2 diabetes at relatively low risk is not known. Earlier
detection of type 2 diabetes and younger age of these patients
cause that patients with lower risk for cardiovascular and
cerebrovascular events are being identiﬁed and treated with
statins [20]. For better guidance on treatment decisions, it is
important to gain an insight into the cost-effectiveness of statin
treatment in patients with type 2 diabetes using the cardiovas-
cular risk estimates and adherence levels based on patient data
from actual practice.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics
The Netherlands.
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treatment for primary prevention, started at the time of diagnosis
of type 2 diabetes, is cost-effective from a health care payers’
perspective in The Netherlands, taking nonadherence, baseline
risk, and age into account.Methods
Markov Model
The cost-effectiveness of statin treatment for primary preven-
tion, started at the time of type 2 diabetes diagnosis, was
determined with a Markov model (Fig. 1). A population with
statin treatment and a population without the use of any lipid-
regulating treatment were simulated with the model. The design
of the model was the same for both populations, with only
probabilities of transitions to events changed by the use of statin
treatment. We assumed that all patients got optimal secondary
prevention. Differences in costs and effects were evaluated.
Because we aimed to determine the cost-effectiveness of
primary prevention, all patients started in the “otherwise
healthy” state, that is, patients with type 2 diabetes having
experienced no previous cardiovascular or cerebrovascular event.
Ten different health states were included in the Markov model,
and patients could shift to another health state after a 1-year
cycle, for which half-cycle corrections were performed [21]. The
adverse events rhabdomyolysis and myopathy were taken into
account. Patients who had experienced an adverse event
returned to the otherwise healthy state in the next run. The
correction for patients discontinuing treatment because of
adverse events was done by applying real-world adherence rates,
which include patients who have stopped statin treatment after
an adverse event. In the base case, a time horizon of 10 years was
used, because we were focusing on primary prevention.
Event Probabilities
Probabilities of shifting to an event state were taken from results
of the United Kingdom Prospective Diabetes Study (UKPDS) risk
engine, with which the annual rates for an event over a 10-year
period can be calculated (see below) [22–24]. When patients
experienced a nonfatal event in the model, they moved to the
“postevent” state in the next cycle. All patients in the cohort
experienced age-speciﬁc probabilities of dying from other causes.
These probabilities were taken from the Dutch lifetime tables,
taking the ageing of the Dutch population explicitly into account
[25]. Because we evaluated primary prevention, we used aMyopathy Otherwise
Fatal CHD Nonfatal CHD
Dea
Post CHD
Fig. 1 – Markov model. CHD,simpliﬁed adjustment on the death rate after the occurrence of
an event. That is, for patients in postevent states, the probabil-
ities of death, taken from Dutch lifetime tables, were increased
twofold based on previous studies [26,27].
The UKPDS risk engine was used to estimate the patients’ 10-
year risks for coronary heart disease (CHD) and stroke on the
basis of patient characteristics, including age, lipid ratio, and
other risk factors [22–24]. These patient characteristics were
obtained from the Groningen Initiative to Analyse Type 2 Dia-
betes Treatment (GIANTT) database. The GIANTT database con-
tains anonymised longitudinal information retrieved from
electronic medical records of general practitioners and is main-
tained by the University Medical Center Groningen [28]. Informa-
tion on age, lipid ratio, and smoking status was taken at the time
of type 2 diabetes diagnosis, in line with Dutch guidelines that
advise statin treatment for patients with type 2 diabetes imme-
diately after diagnosis for practically all patients [9,10]. Because it
is to be expected that hemoglobin A1c and blood pressure values
will decrease after diagnosis because of the initiation of glucose-
lowering and blood pressure–lowering treatment, we averaged
the values for hemoglobin A1c and systolic blood pressure at 1
and 2 years after the diagnosis for estimating the 10-year risks. In
this way, we aimed to estimate the risk factor levels achieved
with such treatment and assumed that patients remain
adequately treated for these other risk factors during follow-up.
This allowed us to assess the risk reduction of statin treatment in
addition to the risk reduction caused by concurrent treatment for
the other risk factors. Clinical data retrieved from the GIANTT
database for a cohort of patients diagnosed with type 2 diabetes
in 2007, 2008, or 2009 were inserted into the UKPDS risk engine.
Patients with a history of CHD or stroke (International Classi-
ﬁcation of Primary Care codes K75, K76, and K90) [29] or who had
a prescription for any lipid-regulating treatment (Anatomical
Therapeutic Chemical (ATC) C10) [30] during the year before
diagnosis were excluded.
In total, 4683 patients with newly diagnosed type 2 diabetes
without a history of cardiovascular and cerebrovascular events
were extracted from the GIANTT database and included in the
UKPDS risk engine. The average patient was aged 61.3 years, and
there were slightly more women than men (51.4%). On average,
patients had a hemoglobin A1c level of 6.7%, systolic blood
pressure of 140 mm Hg, and a lipid ratio of 5 (total cholesterol/
high-density lipoprotein cholesterol); 18% of the patients were
smokers; and 1.6% had atrial ﬁbrillation according to their
medical records.
The average 10-year risk of the population aged 25 to 65 years
at type 2 diabetes diagnosis was 16% for CHD, 8% for fatal CHD,
4% for stroke, and 0.7% for fatal stroke. Stratifying the 10-year Healthy Rhabdomyolysis
Nonfatal stroke Fatal stroke
th
Post stroke
coronary heart disease.
Table 1 – Incidence, effectiveness, disutilities and cost data for the base case.
Parameter Base case Distribution Data source Reference
Annual risks
CHD yearly risk, %
(10-year risk)
1.7, 1.8, 1.9, 2.0, 2.0, 2.1, 2.2,
2.3, 2.4, 2.5 (21%)
Beta Real world data from GIANTT database
inserted in UKPDS risk engine
-
Fatal CHD yearly risk, %
(10-year risk)
0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3,
1.4, 1.5, 1.6 (11%)
Beta Real world data from GIANTT database
inserted in UKPDS risk engine
-
Stroke yearly risk, %
(10-year risk)
0.3, 0.4, 0.4, 0.5, 0.6, 0.6, 0.7,
0.8, 0.9, 1.0 (6%)
Beta Real world data from GIANTT database
inserted in UKPDS risk engine
-
Fatal stroke yearly risk, %
(10-year risk)
0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1,
0,1, 0.2, 0.2 (1%)
Beta Real world data from GIANTT database
inserted in UKPDS risk engine
-
Myopathy (per 100,000
person years)
11 Beta Systematic review 31
Rhabdomyolysis (per
100,000 person years)
3 Beta Systematic review 31
Overall mortality rate
(10-year risk)
12% - Actual rates 25
Statin treatment effectiveness (relative risk)
MI 0.69 Lognormal Meta-analysis 8
Stroke 0.70 Lognormal Meta-analysis 8
Mean adherence rate
First year 81% Beta Real world data from the IADB.nl
prescription database
-
Second year 77% Beta Real world data from the IADB.nl
prescription database
-
Third until tenth year 75% Beta Real world data from the IADB.nl
prescription database
-
Disutility
MI 0.06 Triangular Meta-analysis 37
Stroke 0.22 Triangular Meta-analysis 37
Act of taking statin -0.001 Triangular Assumption 38,39
Annual cost data (€)
Statin treatment
Simvastatin 40 mg € 7.30 - Ofﬁcial tariff 40
Doctor visits € 59.5 - Ofﬁcial tariff 41
Laboratory fee € 20.3 - Ofﬁcial tariff 42
Pharmacists fee € 24.3 - Ofﬁcial tariff 43
Myopathy € 59.5 Gamma Assumption -
Rhabdomyolysis € 11,126 Gamma Cost study 44
MI
First year € 5,012 Gamma Cost study 45
Subsequent years € 1,885 Gamma Cost study 5
Stroke
First year € 13,480 Gamma Cost study 46
Subsequent years € 1,885 Gamma Cost study 5
Death € 2,902 Gamma Assumption 19
CHD, coronary heart disease.
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the risk. Patients aged 56 to 65 years at diagnosis of type 2
diabetes had an average risk of 21% for CHD, 11% for fatal
CHD, 6% for stroke, and 1% for fatal stroke, and patients aged
46 to 55 years had risks of 15%, 6%, 3%, and 0.4%, respectively.
Patients aged 36 to 45 years were estimated to have an average
risk of 9% for CHD, 3% for fatal CHD, 1% for stroke, and 0.1% for
fatal stroke.
Statin Treatment and Adherence
Statin efﬁcacy was modeled by implementing the relative risk
reduction found in a recent meta-analysis of randomized clinical
trials on the primary prevention of cardiovascular and cerebro-
vascular events in patients with diabetes with statins [8]. Overall
relative risk reductions of 31% for nonfatal CHD and fatal CHDand 30% for nonfatal stroke and fatal stroke were applied. The
risks for adverse events myopathy and rhabdomyolysis were
taken from a systematic review [31].
Adherence to statins was modeled by using real-world data
from the IADB.nl database, which is a pharmacy research data-
base in The Netherlands with a sample of the Dutch population of
500,000 persons. Patients with type 2 diabetes and no history of
cardiovascular and cerebrovascular events were identiﬁed by the
use of medication proxies (Appendix I). Statin adherence rates
were deﬁned as the percentages of pill days covered (PDC) [32].
Adherence rates were measured for patients starting statin treat-
ment from 2008 up to and including 2010 (ATC C10AA, C10BA, and
C10BX). Patients were considered as a starter of statin treatment
when they did not use any lipid-lowering medication (ATC C10) in
the year before the start of the statin treatment. Adherence rates
were measured up to a maximum of 3 years, and in the base case
Table 2 – One-way sensitivity analyses (base case
values between brackets).
Assumption Cost-
effectiveness
Base case €2,245
Statin costs (€7.3)
€18.5 (actual costs IADB.nl population) €2,644
€50 €3,766
€100 €5,547
Myopathy (11 op 100.000 years)
100 €2,247
Discounting rate (effects 1.5%;costs 4%)
Effects 3%; costs 3% €3,041
Effects 4%; costs 4% €3,144
Disutility taking a pill (0.999)
No disutility €2,155
Time horizon (10 years)
5 years €12,424
Adherence rate (81%, 75%, 77% respectively
ﬁrst, second and subsequent years)
Full adherence (80-100% PDC) in all years €1,534
50% adherence in all years €3,312
Adherence decreasing 2% each year after
year 3
€2,266
Adherence decreasing 5% each year after
year 5
€2,297
Relation statin efﬁcacy and non-adherence
(≥80%=1;20-80%=linear;≤20%=0)
≥70%=1;30-70%=linear;≤30%=0 €2,217
≥80%=1;0-80%=linear €2,175
≥60%=1;0-50%=linear €2,108
UKPDS risk overestimation
Lowering risk with 50% €6,500
Table 3 – Outcomes of the cost-effectiveness analysis str
Age (y) 10-y risk for CHD; fatal CHD;
stroke; fatal stroke
Proportion
age group
o45* 1. 3; 1; 1; 0 27.5
2. 6; 1; 1; 0 28.5
3. 9; 3; 1; 0 21.8
4. 13; 4; 2; 0 9.5
5. 16; 6; 3; 1 12.7
45–55║ 1. 6; 2; 1; 0 21.1
2. 10; 4; 2; 0 28.7
3. 15; 6; 3; 0.5 20.8
4. 20; 7; 4; 0.5 16.7
5. 26; 10; 5; 1 12.6
55–65¶ 1. 6; 3; 3; 1 6.8
2. 10; 4; 3; 1 30.4
3. 21; 11; 6; 1 34.7
4. 27; 13; 7; 1 15.9
5. 35; 24; 9; 2 12.3
Note. inferior ¼ no cost-effectiveness is calculated because of the nega
adjusted life-year.
* Weighted cost-effectiveness for treating all patients with diabetes you
† 4€80,000.
‡ €50,000–€80,000.
§ o€20,000.
║ Weighted cost-effectiveness for treating all patients with diabetes betw
¶ Weighted cost-effectiveness for treating all patients with diabetes betw
#€20,000–€50,000.
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was observed in a previous study [17].
Nonadherence was modeled by reducing the statin efﬁcacy.
Statin treatment with 80% or more PDC was assumed to be
associated with full efﬁcacy [33]. Patients with 20% or less PDC
were assumed to be associated with no efﬁcacy of the statin
treatment. Efﬁcacy of intermediary levels of PDC was approxi-
mated with linear interpolation in the base case because studies
indicate that there is a linear association between adherence
levels and reductions in low-density lipoprotein cholesterol and
in hospitalizations [34–36].
In 1660 patients who started statin treatment, the mean PDC
was 81% during their ﬁrst year of statin use. Adherence rates
decreased to 77% and 75% in year 2 and 3, respectively. In total,
1049 patients were followed for at least 2 years and 479 for 3
years. Because we allowed new users to be included during the
study period, some patients could be followed only for 1 year. The
decrease in the number of patients in the follow-up years was
mainly due to later inclusion into the study rather than early
dropout.Health Effects and Costs
We determined the difference in quality-adjusted life-years
(QALYs) between no lipid-regulating treatment and treatment
with a statin. QALYs were calculated by multiplying the time in a
speciﬁc health state with the quality of life associated with the
health state. For patients experiencing a CHD or stroke, disutility
scores were 0.06 and 0.22, respectively [37]. These utility scores
were constant over time. A small disutility of 0.001 for taking a
statin pill every day was included [38,39].
All cost estimates were updated to 2012 euros with the Dutch
consumer price indices (http://statline.cbs.nl). Annual costs for
statin treatment in the base case were based on statin pill costs
(€7.3 for 40 mg generic simvastatin) [40], two GP visits (€59.5) [41],atiﬁed by age and risk for CHD and stroke
per QALYs 1,000
patients
Costs per 1,000
patients (€)
Cost-
effectiveness
8 814,012 Inferior†
3 789,256 Inferior†
11 738,926 €66,537‡
43 689,576 €16,085§
77 634,993 €8,223§
9 758,216 88,440†
49 674,895 €13,828§
75 623,327 €8,345§
96 559,641 €5,810§
145 486,131 €3,353§
43 638,881 €14,824§
61 618,594 €10,119§
193 432,890 €2,245§
197 382,633 €1,939§
453 276,148 €609§
tive effect on QALYs. CHD, coronary heart disease; QALY, quality-
nger than 45 years in The Netherlands ¼ €57,244.
een 45 and 55 years in The Netherlands ¼ €8,295.
een 55 and 65 years in The Netherlands ¼ €2,480.
0 1000 2000 3000 4000
Efficacy statins on CHD
Baseline risk CHD
Adherence rate
Efficacy statins on Stroke
CHD subsequent years costs
Baseline risk Stroke
Stroke subsequent years costs
Stroke event costs
drug costs
CHD event costs
Stroke utility
CHD utility
Rhabdomyolysis rate
Rhabdomyolysis costs
Fig. 2 – Tornado diagram; all parameters are increased and decreased with 25%. CHD, coronary heart disease.
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cists’ prescription fees (€23) [43]. Event costs were based on the
literature (Table 1).Economic Analysis
The model was run over a time horizon of 10 years. Costs were
discounted at 4% and health effects at 1.5%, following the Dutch
guidelines [41]. In the base case, a 60-year-old patient was
assessed, based on the average age of 61.3 years at type 2 diabetes
diagnosis in the GIANTT database population. Mean 10-year
cardiovascular risks of patients aged 56 to 65 years at type 2
diabetes diagnosis were used. With the use of a tornado diagram,
the effect of the parameters on the outcome of the cost-Fig. 3 – Cost-effectiveness acceptability curveseffectiveness was assessed. In addition, the effects of age and
baseline risk for CHD and stroke were evaluated. To assess the
effect of individual parameters that may vary between countries
or that were based on assumptions, one-way sensitivity analyses
were performed. This included sensitivity analyses for statin
costs, adverse event rates, discounting rates, disutility of taking
a pill every day, time horizon, adherence rates, and relation
between nonadherence and efﬁcacy. Parameter variations tested
are presented in Table 2. We also included a one-way sensitivity
analysis to account for the possible overestimation by using the
UKPDS risk engine, assuming a maximum reduction of 50% in the
estimates [47]. Finally, a probabilistic sensitivity analysis with
5000 iterations was performed to deal with parameter uncer-
tainty [48]. The parameter distributions used are listed in Table 1.from the probabilistic sensitivity analysis.
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Economic Analysis
In the base case, cost-effectiveness is €2245 per QALY (Table 2).
Sensitivity analyses were performed to investigate differences in
risks for CHD and stroke according to age. In Table 3, the
outcomes of the cost-effectiveness analysis are shown stratiﬁed
by age and 10-year risks for CHD and stroke. The risks chosen for
each age group were based on actual risk ranges within the
GIANTT database population. Treating all type 2 patients younger
than 45 years for primary prevention of cardiovascular and
cerebrovascular events was not cost-effective, with costs of
€57,243 per QALY. Treating all patients aged 45 to 55 years at
diagnosis was cost-effective, with costs of €8295 per QALY. For
21.1% of the patients, however, cost-effectiveness would be high
and not cost-effective (Table 3).
The tornado diagram (Fig. 2) shows that the efﬁcacy of the
statins, the baseline risk for CHD and stroke, and the adherence
rates have a large effect on the outcome of the cost-effectiveness.
In the one-way sensitivity analyses (Table 2), statin costs also
have a major effect on the cost-effectiveness. In The Netherlands,
statin costs for 40 mg generic simvastatin were only €7.3
annually. The actual annual statin costs per patient in the
IADB.nl population were €18.5, which results in a negative effect
on cost-effectiveness (€2644 per QALY). Changing the time
horizon to 5 years will lead to a substantial increase in costs
(€12,424 per QALY). Increasing adherence to statin treatment will
improve cost-effectiveness. Full adherence reduces the costs to
€1534 for the base case. However, changing the assumptions on
the adherence rate after year 3 does not have a great effect on
cost-effectiveness (Table 2).
The acceptability curves of the probabilistic sensitivity analyses
in Figure 3 show that the probability that statin treatment is cost-
effective for the average 60-year-old patient is 100%, using a thresh-
old of €20,000 per QALY. Considering the average 40-year-old
patient, the analysis shows that with this threshold of €20,000 per
QALY, the probability that it is cost-effective is less than 15% (Fig. 3).Conclusions
We estimated that statin treatment for primary prevention start-
ing at the time of diagnosis of type 2 diabetes is cost-effective at
€2245 per QALY in the base case. There is great diversity in the
risks for CHD and stroke in the type 2 diabetes population.
Differences in age and 10-year risks for CHD and stroke result in
large differences in cost-effectiveness from losing QALYs to being
almost cost neutral. With the adherence rates seen in practice, it
can be concluded that treating all patients younger than 45 years
with type 2 diabetes at diagnosis with statins for primary
prevention is not cost-effective. For patients aged between 45
and 55 years at diagnosis, statin treatment is cost-effective except
when the 10-year risk for CHD is as low as 6%. For the other
patients, statin treatment is expected to be cost-effective.
Our ﬁnding that statin treatment for primary prevention is cost-
effective for the average 60-year-old patient is in line with other
pharmacoeconomic analyses [14–16]. The ﬁnding that statin treat-
ment is not cost-effective in patients at low risk is in line with
ﬁndings from Greving et al. [19]. Cost-effectiveness, however,
appears slightly better in our diabetes population. For a 65-year-
old patient with a 10-year risk of 15%, Greving et al. estimated the
costs at €12,652 per QALYwhereas we estimated the costs at €10,119
per QALY for a 60-year-old patient with a 10-year risk of 13%.
Currently, there are more than 800,000 patients with diabetes
in The Netherlands [49]. Within the GIANTT database population,14% of the patients have a cardiovascular history, implying that
688,000 patients might be eligible for primary prevention with
statin treatment. With the current price levels, such statin treat-
ment would cost the Dutch health care system around €75.7
million each year. The broad range for cost-effectiveness between
the individual patients suggests that the efﬁciency of the treat-
ment could be increased by focusing on patients with higher
cardiovascular risk and higher ages. Within the GIANTT database
primary prevention population, 19% of the patients had an age at
diagnosis of less than 50 years in whom starting statin treatment
at the time of diagnosis may not be cost-effective.
Cost-effectiveness was assessed taking various parameters
into account, such as adherence and adverse events. Adherence
to statin treatment obviously plays an important role in cost-
effectiveness analysis. In our study population, adherence rates
for statin treatment were higher than reported in other studies
[17,50]. Nevertheless, further improving adherence would lead to
improvements in cost-effectiveness. Furthermore, in the base-
case analysis, the statin costs of 40 mg generic simvastatin (€7.3)
were applied; use of the average annual costs of statin treatment
from the IADB.nl population (€18.5) has a minor negative effect
on cost-effectiveness. Dutch guidelines [9,10] recommend 40 mg
simvastatin or 40 mg pravastatin (€16.10) when statin treatment
is started. Treating patients with 40 mg simvastatin has beneﬁ-
cial effects on cost-effectiveness. Nevertheless, some patients
need a switch to more expensive statins to reach lipid goals [51].
In the base-case analysis, we chose a time horizon of 10 years.
Shortening the time horizon to 5 years clearly affects the cost-
effectiveness, indicating that primary prevention with statins is
especially beneﬁcial in patients with diabetes who can and will
take the treatment for a longer period.
Strengths
We analyzed the baseline risk of a population of patients with type
2 diabetes using observational patient data that were inserted into
the UKPDS risk engine. Because the GIANTT database cohort
includes an unrestricted population of patients with type 2 diabetes
in primary care, these data better reﬂect the population treated
with statins in actual practice as compared to the patients included
in trials. Adherence rates were also measured in the actual
population. Both populations were taken from the Northern part
of The Netherlands. Using the tornado diagram, the parameters
that have a large effect on the outcome of the cost-effectiveness
analysis—such as the efﬁcacy of statins, the baseline risk for CHD
and stroke, and adherence rates—were analyzed in detail. From
this, it becomes clear that the utilities and the drug costs did not
have a large effect on the results. The strength of this study is that
we stratiﬁed the patients according to age. As a result of the broad
ranges in the 10-year risks for CHD and stroke between the different
age groups, broad variations in cost-effectiveness could be shown.
Limitations
First, the UKPDS risk engine was used for determining cardiovas-
cular risks for patients with type 2 diabetes. There is evidence
that the UKPDS risk engine overestimates the risks for CHD and
stroke [47,52]. As shown in the sensitivity analysis, the costs per
QALY could more than double when risks are overestimated by a
factor of 2. It seems, however, that at the risk levels seen in the
primary prevention diabetes population, the overestimation is
probably not that high [47]. Second, adherence rates of the
patients were measured in a pharmacy research database in
which the indication of the patient was not known. Medication
proxies had to be used for identifying diabetes primary preven-
tion patients. The proxy for diabetes is known to give a high
sensitivity [53]. The proxy for primary prevention showed a high
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can be expected to be secondary prevention patients. Third, the
adherence rates were measured only for the ﬁrst 3 years and
assumed to stay constant over time afterwards. In addition, for
the intermediate adherence levels, we assumed a linear relation
with the efﬁcacy. Although there is some evidence that these
assumptions are acceptable [17,34–36], we tested them in the
sensitivity analyses, which showed that various changes in the
assumptions did not have much effect on the results. We used
real patient data for the risk estimation and adherence rates, but
treatment efﬁcacy, disutilities, and cost data were based on
literature. For statin efﬁcacy as well as for post–myocardial
infarction and poststroke utilities, we made use of estimates
from meta-analyses, which applied minimum criteria for includ-
ing appropriate data. For costs, we tried to retrieve the most
recent data available but had to rely on multiple sources pub-
lished in the past decade. Only direct health care costs were
included. Including indirect costs would obviously be favorable
for cost-effectiveness [45,46].
This study is an illustration for The Netherlands. In The
Netherlands, statin costs are very low, and such medication is
reimbursed for all patients. Other countries may have higher
statin costs or higher nonadherence rates due to patient co-
payments, and cost-effectiveness might be less favorable. The
population used in this analysis was from the northern part of The
Netherlands, which is known to have a lower rate of immigrants
and a lower socioeconomic status in comparison to other parts of
The Netherlands [54,55]. As one could speculate that this might
affect the estimated risks for cardiovascular events and the
adherence rates in opposite directions, it is not clear to what
extent this would result in relevant changes in our ﬁndings.
We used a time horizon of 10 years with cycle lengths of 1 year.
Because of data availability, it was not possible to shorten the cycle
length but by performing half-cycle corrections, the effect of this
longer cycle length was minimized. Because we aimed to assess
the effect of primary prevention of cardiovascular and cerebrovas-
cular events, we did not perform a lifetime analysis but did shorten
the time horizon in the sensitivity analysis to 5 years.
In general, primary prevention with statin treatment at the time
of diagnosis is not cost-effective for all patients with type 2 diabetes.
In the recent Dutch guidelines for cardiovascular management, 40
years is mentioned as the age limit for patients with diabetes below
which statin treatment would seldom be indicated [9]. Our study
indicates that this age limit may be set higher because, on average,
starting statin treatment in patients younger than 45 years is not
expected to be cost-effective. However, our results indicate that
statin treatment, even with the levels of nonadherence and
variations in choice of statin seen in actual practice, is highly
cost-effective for patients older than 55 years at diagnosis with a
time horizon of 10 years. Although it is acknowledged that there is
no single treatment appropriate for all patients and the individual
risk proﬁle of a patient should be considered, these simple age-
based recommendations could be helpful for guiding practice.
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